Center for Prostate Cancer, Goyang, Korea.
J Korean Med Sci. 2010 Sep;25(9):1291-5. doi: 10.3346/jkms.2010.25.9.1291. Epub 2010 Aug 12.
We investigated whether the detection of prostate specific membrane antigen (PSMA) in blood preoperatively has predictive value for biochemical recurrence (BCR) after radical prostatectomy in patients with prostate cancer. All 134 patients scheduled to receive radical prostatectomy for prostate cancer were prospectively enrolled. The authors used nested reverse transcriptase-polymerase chain reaction (RT-PCR) assay to detect PSMA mRNA-bearing cells in peripheral blood, and analyzed the ability of PSMA mRNA positivity to predict BCR after surgery. PSMA-mRNA was detected in 24 (17.9%) patients by RT-PCR. Over a median follow-up of 20 months (range, 3 to 46 months), BCR developed in 15 patients (11.2%) and median time to BCR was 7 months (range, 3 to 25 months). Kaplan-Meier analysis revealed a significant difference between those positive or negative for PSMA in terms of recurrence-free actuarial probability (log rank P=0.0039). Multivariate analysis showed that positivity for PSMA mRNA (HR: 3.697, 95% CI 1.285-10.634, P=0.015) and a biopsy Gleason score of >or=7 (HR: 4.500, 95% CI 1.419-14.274, P=0.011) were independent preoperative predictors of BCR. The presence of PSMA mRNA in peripheral blood can be used to predict BCR after radical prostatectomy.
我们研究了前列腺特异性膜抗原(PSMA)在术前血液中的检测是否对前列腺癌患者根治性前列腺切除术后生化复发(BCR)有预测价值。所有 134 例计划接受根治性前列腺切除术治疗前列腺癌的患者均前瞻性入组。作者使用巢式逆转录聚合酶链反应(RT-PCR)检测外周血中携带 PSMA mRNA 的细胞,并分析 PSMA mRNA 阳性预测术后 BCR 的能力。作者通过 RT-PCR 在 24 例(17.9%)患者中检测到 PSMA-mRNA。中位随访 20 个月(范围,3 至 46 个月)后,15 例(11.2%)患者发生 BCR,中位时间为 7 个月(范围,3 至 25 个月)。Kaplan-Meier 分析显示,PSMA 阳性或阴性患者在无复发生存 actuarial 概率方面存在显著差异(对数秩 P=0.0039)。多变量分析显示,PSMA mRNA 阳性(HR:3.697,95%CI 1.285-10.634,P=0.015)和活检 Gleason 评分≥7(HR:4.500,95%CI 1.419-14.274,P=0.011)是 BCR 的独立术前预测因子。外周血中 PSMA mRNA 的存在可用于预测根治性前列腺切除术后的 BCR。